MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 526040 | Name: Mirtazapine dihydrochloride

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Mirtazapine is an atypical antidepressant with noradrenergic and specific serotonergic activity. It works by blocking the α2 adrenergic auto- and heteroreceptors (enhancing serotonin release), and selectively antagonizing the 5-HT2 and 5-HT3 serotonin receptors in the central and peripheral nervous system. It also enhances serotonin neurotransmission at the 5-HT1 receptor and blocks the histaminergic (H1) and muscarinic receptors. Mirtazapine is not a serotonin or norepinephrine reuptake inhibitor.

Chemical Structure

Mirtazapine dihydrochloride
Mirtazapine dihydrochloride
CAS#207516-99-2 (2HCl),

Theoretical Analysis

MedKoo Cat#: 526040

Name: Mirtazapine dihydrochloride

CAS#: 207516-99-2 (2HCl),

Chemical Formula: C17H21Cl2N3

Exact Mass: 265.1579

Molecular Weight: 338.28

Elemental Analysis: C, 60.36; H, 6.26; Cl, 20.96; N, 12.42

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
85650-52-8 (free base) 61337-67-5 (deleted) 1448014-35-4 (HCl) 868528-74-9 (HBr) 207516-99-2 (2HCl) 341512-89-8 (hemihydrate) 868363-97-7 (HBr) 207516-99-2 (HCl) 1216678-68-0 (deuterated forms d3)
Synonym
Mirtazapine 2HCl; Mirtazapine; ORG-3770; ORG 3770; ORG3770; Mirtazapine dihydrochloride
IUPAC/Chemical Name
2-Methyl-1,2,3,4,10,14b-hexahydrobenzo[c]pyrazino[1,2-a]pyrido[3,2-f]azepine dihydrochloride
InChi Key
MINYXDMRFGBVNN-UHFFFAOYSA-N
InChi Code
InChI=1S/C17H19N3.2ClH/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20;;/h2-8,16H,9-12H2,1H3;2*1H
SMILES Code
CN(CC1)CC2N1C3=NC=CC=C3CC4=CC=CC=C24.[H]Cl.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 338.28 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kato M, Baba H, Takekita Y, Naito M, Koshikawa Y, Bandou H, Kinoshita T. Usefulness of mirtazapine and SSRIs in late-life depression: post hoc analysis of the GUNDAM study. Eur J Clin Pharmacol. 2023 Sep 13. doi: 10.1007/s00228-023-03563-8. Epub ahead of print. PMID: 37700038. 2: Zhou J, Zhao Y, Dai J, Zhang K. Environmentally relevant concentrations of antidepressant mirtazapine impair the neurodevelopment of zebrafish (Danio rerio). Ecotoxicol Environ Saf. 2023 Aug 8;262:115335. doi: 10.1016/j.ecoenv.2023.115335. Epub ahead of print. PMID: 37567106. 3: Barbosa-Méndez S, Salazar-Juárez A. Estradiol enhances the mirtazapine effects on the expression of cocaine-induced locomotor sensitization in female rats. Behav Pharmacol. 2023 Sep 1;34(6):362-374. doi: 10.1097/FBP.0000000000000743. Epub 2023 Aug 2. PMID: 37530137. 4: Almeida OLS, Ferriolli E, Taveira RCC, Rosenburg MG, Campanari DD, da Cruz Alves NM, Pfrimer K, Rapatoni L, Peria FM, Lima NKC. Mirtazapine versus Megestrol in the Treatment of Anorexia-Cachexia Syndrome in Patients with Advanced Cancer: A Randomized, Double-Blind, Controlled Phase II Clinical Trial. Cancers (Basel). 2023 Jul 12;15(14):3588. doi: 10.3390/cancers15143588. PMID: 37509249; PMCID: PMC10377007. 5: Kubera M, Arteta B, Grygier B, Curzytek K, Malicki S, Maes M. Stimulatory effect of fluoxetine and desipramine, but not mirtazapine on C26 colon carcinoma hepatic metastases formation: association with cytokines. Front Immunol. 2023 Jun 20;14:1160977. doi: 10.3389/fimmu.2023.1160977. PMID: 37409130; PMCID: PMC10318584. 6: Alharthy SA, Zughaibi TA, Vij P, Tabrez S, Almashjary MN, Alharthi S, Alamri T, Alghamdi BS, Harakeh S, Azhari SA, Farsi RM, Althagafy HS, Hassanein EHM. Mirtazapine attenuated cadmium-induced neuronal intoxication by regulating Nrf2 and NF-κB/TLR4 signals. Toxicol Mech Methods. 2023 Jul 4:1-13. doi: 10.1080/15376516.2023.2231530. Epub ahead of print. PMID: 37403423. 7: Ghazwani M, Vasudevan R, Kandasamy G, Manusri N, Devanandan P, Puvvada RC, Veeramani VP, Paulsamy P, Venkatesan K, Chidmabaram K, Dhurke R. Formulation of Intranasal Mucoadhesive Thermotriggered In Situ Gel Containing Mirtazapine as an Antidepressant Drug. Gels. 2023 Jun 2;9(6):457. doi: 10.3390/gels9060457. PMID: 37367128; PMCID: PMC10297899. 8: Gupta N, Gupta M. Diagnostic Overshadowing in High-Functioning Autism: Mirtazapine, Buspirone, and Modified Cognitive Behavioral Therapy (CBT) as Treatment Options. Cureus. 2023 May 24;15(5):e39446. doi: 10.7759/cureus.39446. PMID: 37362512; PMCID: PMC10289477. 9: Otsuki K, Tsukitaku M, Sato K, Sunami M, Inagaki M. A Case of Akathisia After Administration of a Very Low Dose of Mirtazapine. J Clin Psychopharmacol. 2023 Jul-Aug 01;43(4):378-379. doi: 10.1097/JCP.0000000000001708. Epub 2023 May 29. PMID: 37235510. 10: Umezaki Y, Motomura H, Egashira R, Toyofuku A, Naito T. A Case of Oral Cenesthopathy Treated With the Combination of Brexpiprazole and Mirtazapine. Clin Neuropharmacol. 2023 May-Jun 01;46(3):123-125. doi: 10.1097/WNF.0000000000000545. Epub 2023 Mar 10. PMID: 37191566. 11: Aslam H, Ahmed K, Iskander PA, Aloysius MM, Khurana V, Nasr S, Amjad MA. A Case of Mirtazapine-Induced Pancreatitis. Cureus. 2023 Apr 4;15(4):e37129. doi: 10.7759/cureus.37129. PMID: 37153315; PMCID: PMC10159629. 12: Huang CC, Kuo SC, Chen CY, Yeh YW. Hypereosinophilia and Cognitive Impairment Induced by Mirtazapine. Am J Ther. 2023 Apr 20. doi: 10.1097/MJT.0000000000001632. Epub ahead of print. PMID: 37097041. 13: Jamshidfar N, Hamdieh M, Eslami P, Batebi S, Sadeghi A, Rastegar R, Dooghaie Moghadam A, Masjedi Arani A. Comparison of the potency of nortriptyline and mirtazapine on gastrointestinal symptoms, the level of anxiety and depression in patients with functional dyspepsia. Gastroenterol Hepatol Bed Bench. 2023;16(1):468-477. doi: 10.22037/ghfbb.v16i1.2513. PMID: 37070114; PMCID: PMC10105507. 14: Šakić B, Greš A, Gajić Z. Mirtazapine-Induced Hyponatremia in a Patient with Systemic Mastocytosis and Generalized Anxiety Disorder. Psychiatr Danub. 2023 Spring;35(1):126-127. doi: 10.24869/psyd.2023.126. PMID: 37060606. 15: Dell'Osso L, Lorenzi P, Nardi B, Carpita B, Benedetti F, Cremone IM. Occurrence of Terrifying Nightmares after Few Days of Mirtazapine Use in Elderly Patients. Case Rep Psychiatry. 2023 Apr 4;2023:8843206. doi: 10.1155/2023/8843206. PMID: 37057036; PMCID: PMC10089773. 16: Maidwell-Smith A, Kirk C. Mirtazapine-induced neutropenic sepsis in an older person: a case report. J Med Case Rep. 2023 Apr 14;17(1):163. doi: 10.1186/s13256-023-03881-6. PMID: 37055872; PMCID: PMC10103480. 17: Hawkins M. A 9-year-old female with iron deficiency has severe periodic limb movements while taking mirtazapine for insomnia. J Clin Sleep Med. 2023 Jul 1;19(7):1369-1373. doi: 10.5664/jcsm.10580. Epub ahead of print. PMID: 37032615; PMCID: PMC10315591. 18: Jørgensen CK, Juul S, Siddiqui F, Horowitz MA, Moncrieff J, Munkholm K, Hengartner MP, Kirsch I, Gluud C, Jakobsen JC. The risks of adverse events with venlafaxine and mirtazapine versus 'active placebo', placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis. Syst Rev. 2023 Mar 30;12(1):57. doi: 10.1186/s13643-023-02221-5. PMID: 36991504; PMCID: PMC10061867. 19: Aldeeb RAE, Mahdy MAE, El-Nahas HM, Musallam AA. Design of mirtazapine solid dispersion with different carriers' systems: optimization, in vitro evaluation, and bioavailability assessment. Drug Deliv Transl Res. 2023 Sep;13(9):2340-2352. doi: 10.1007/s13346-023-01316-9. Epub 2023 Mar 20. PMID: 36940079; PMCID: PMC10382405. 20: Abdelhady R, Cavalu S, Saber S, Elmowafy R, Morsy NE, Ibrahim S, Abdeldaiem MSI, Samy M, Abd-Eldayem MA, Shata A, Elgharabawy RM. Mirtazapine, an atypical antidepressant, mitigates lung fibrosis by suppressing NLPR3 inflammasome and fibrosis-related mediators in endotracheal bleomycin rat model. Biomed Pharmacother. 2023 May;161:114553. doi: 10.1016/j.biopha.2023.114553. Epub 2023 Mar 17. PMID: 36934553.